|
| ICTS Digest | September 2026
|
|
|
|
ICTS Investigator and Former KL2 Scholar Awarded NIA Funding for Alzheimer’s Caregiver Research |
Jacquelyn Benson, PhD, Associate Professor of Medicine in the WashU Division of Palliative Medicine, has recently been awarded funding from the National Institute on Aging to conduct a randomized controlled trial to test a 1:1, paraprofessional peer-delivered multicomponent support intervention for family caregivers of persons living with Alzheimer’s disease (AD). On her path to achieving this funding, Benson praises the ICTS resources she has utilized and expresses how impactful said resources have been on furthering her research.
|
ICTS Resource Spotlight - K12 Mentored Research Career Development Program |
|
|
|
Please join us for an informational session to discuss the future K12 program (currently named “KL2”), administered by the Clinical Research Training Center (CRTC).
The session will be held virtually on Monday, November 2, 2026 from 2:00-3:00 pm. Speakers will include both KL2/CRTC leadership and KL2 alumni.
Email the ICTS at icts@wustl.edu to be added to the invitation!
|
|
|
Speakers: (top-l-r) Drs. Nancy Sweitzer, Dominic Reeds, and Patricia Cavazos-Rehg (bottom-l-r) Drs. James Krings and Lauren Roland
|
|
|
|
Last Chance to Submit LOI for ICTS Winter NIH Mock Study Section! |
|
|
|
The ICTS Research Development Program will host the Winter NIH Mock Study Section (MSS) for clinical and translational grants on Wednesday, Nov. 18, 2026. Participants will be able to:
- Learn about the NIH process
- Make your NIH R, K or F series grant competitive
- Receive timely feedback
Letters of Intent due: Sept. 23, 2026 (by 5pm CT)
Full proposals (if invited) due: Oct. 14, 2026 (by 5pm CT)
Mock Study Section: Nov. 18, 2026 (8am - 5pm CT)
(Zoom virtual meeting – invitation only)
|
|
| |
|
ICTS JIT Core Spotlight - Intellectual and Developmental Disabilities Research Center (IDDRC) |
|
|
|
The IDDRC provides consultation, core resources, and technical expertise for comprehensive IDD clinical, behavioral, and genomic research through magnetic resonance and optical imaging in human and animal models; and characterization and reprogramming of human somatic cell and animal models of IDD, including behavioral characterization in the Animal Behavior Subunit.
|
|
| |
|
CRTC Celebrates the 2nd Cohort of Clinical Research Professional Apprentices! |
|
|
|
After 240 hours of classroom learning and 2,000 hours of hands-on experience, the second cohort of Clinical Research Professional Apprentices successfully completed the program this summer! We would like to extend a huge congratulations to this year's graduates: Harmon Kreuger and Mounia El Kalai. The Clinical Research Professional (CRP) Apprenticeship is a 12-month program combining on-the-job learning and related instruction in theoretical, technical, and application training.
|
|
| El Kalai (left) and Kreuger
|
|
|
|
As a Clinical and Translational Science Award Hub, we are eligible for limited competitions, including U01, R21, U24, and other grant mechanisms.
View all funding opportunities
|
|
| |
|
Research Education & Training |
|
|
|
CRTC Calls for Applications for Mentored Training Program in Clinical Investigation (MTPCI) and Master of Science in Clinical Investigation (MSCI)
Through didactic coursework and structured mentorship, the Mentored Training Program in Clinical Investigation (MTPCI) and Master of Science in Clinical Investigation (MSCI) are designed to prepare junior faculty and young investigators for academic careers in clinical research and take investigators’ careers to the next level. Scholars will advance training in clinical investigation by learning how to develop effective research projects, consider relevant ethical and legal issues, write grants and manuscripts, and more. Applications for both programs are due by November 1, 2026.
|
|
|
Register Now for the MU NextGen Clinical Trial Investigator Training Program
The NextGen Clinical Trial Investigator Training is one-day in-person educational program designed for investigators who currently lead or would like to lead clinical trials. The series includes lectures and panel discussions aimed to define the regulatory, operational and ethical components of clinical trials, with the goal of developing a skilled workforce that provides the highest level of patient safety, teamwork and data quality. The in-person training will be held at the University of Missouri on October 9, 2026 from 8:00 am - 4:00 pm.
|
|
|
|
Save the Date for ACTS Translational Science 2027
Join the translational science community in Washington DC on April 20-23, 2027 for Translational Science 2027 (TS27). Connect with researchers, clinicians and professionals to exchange ideas, discover emerging research and foster collaboration across the field. Have research or insights to share? Submit a proposal for a scientific session or poster presentation and contribute to the TS27 program. Scientific session proposals are due by September 14, 2026 and poster proposals are due by October 19, 2026.
|
|
| |
|
NIH To Replace Letters of Support with Letters of Collaboration in Funding Applications
With the implementation of Forms J in the federal fiscal year 2027, the NIH has announced that it will no longer allow letters of support but will instead require letters of collaboration to document any collaborative relationships with individuals who are not identified in the application as senior/key personnel or other significant contributors. Applications that continue to include letters of support after the implementation date may be returned without review. Traditional letters of support for non-NIH applications can be requested from the ICTS by emailing icts@wustl.edu.
|
|
| |
|
Our address is:
Washington University Institute of Clinical and Translational Sciences
660 South Euclid Avenue, MSC 8066-22-03
St. Louis, MO 63110-1093
Phone: (314) 362-9829
|
*Cite the NIH CTSA Grant Number UL1TR002345 when your research was supported by ICTS/CTSA funds or services*
|
|
|
|
1 Brookings Dr | St Louis, MO 63130 US
|
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
Opt Out using TrueRemove™
|
| |
|
|
